The study demonstrated that overexpression of HER2 led to increases in STAT1 and ACTA2 in EGFR+ breast cancer cells, whereas the use of the STAT1 inhibitor fludarabine resulted in decreased ACTA2 mRNA and HER2 protein levels [81]. The gene discussed is ERBB2; the disease is breast carcinoma.